A Phase 1 interventional study of Ruxolitinib in Myelofibrosis, sponsored by Incyte Corporation. Completed at 18 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 14th largest by enrollment, is one of 6 that started in 2011, is one of 12 in phase 1, and was the 5th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
23 studies in Primary Myelofibrosis by Incyte Corporation: 3 open now, 6 under way, none of them phase 3. Of 17 finished, 14 (82%) have results posted.
Among the 23 studies in Primary Myelofibrosis by Incyte Corporation, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2011, is one of 7 in phase 1, and was the 3rd registered.
Incyte Corporation’s Primary Myelofibrosis studies by the year they started, since 2007.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Incyte Corporation’s 23 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF). The study consists of two periods: the core study period, comprising the dose escalation stage and the safety extension phase up to Week 24, then the extension study period beyond Week 24 and up to 3 years, to further characterize the safety and efficacy of ruxolitinib in this patient population. The dose escalation phase will enroll successive cohorts of patients who receive increasing doses of ruxolitinib until the maximum safe starting dose (MSSD) is determined. In the safety expansion phase, additional patients will be treated with ruxolitinib at the MSSD defined during dose escalation. The primary objective is to establish the MSSD of ruxolitinib in patients with MF and starting platelet counts \< 100 x 10 \^9/L
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with baseline Platelet counts of 75-99 x10\^9/L
Drug: Ruxolitinib
Participants with baseline Platelet counts of 50-74 x10\^9/L
Drug: Ruxolitinib
Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID) Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count
Also known as: INCB018424
Number of Participants With Dose Limiting Toxicities
DLT was defined as the occurrence of any of the following treatment-related toxicities, occurring through Day 28: Any grade ≥ 2 hemorrhagic event ; Any grade thrombocytopenia requiring PLT transfusion; PLT count \< 25x109/L\*; Grade 4 neutropenia (absolute neutrophil count \< 0.5x109/L)\*; Grade ≥ 3 febrile neutropenia\*; Grade ≥ 2 total serum bilirubin with coincident direct bilirubin ≥ 0.5 mg/dL; Grade 3 non-hematologic toxicity for ≥ 7 consecutive days; Grade 4 non-hematologic toxicity. In the dose escalation stage in the core study period, the starting does in both strata was 5mg bid. Successive cohorts of newly enrolled patients received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined. Initially, only patients with PLT counts 75-99 x10\^9/L (stratum 1) were allowed to be enrolled. Once safety was established in stratum 1 at the first 2 dose cohorts, eligible population was further expanded to patients with PLT counts 50-74 x10\^9/L (stratum 2).
Time frame: 28 days
Number of Treatment Emergent Adverse Events (TEAE's)
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
Time frame: approximately 4 years
Number of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length
Participants achieving ≥ 50% reduction in palpable spleen length relative to study day 1 by treatment and stratum
Time frame: 24 weeks
Change in Spleen Length as Measure by Palpation Over Time
Defined as measurement of change in spleen length by palpation from baseline
Time frame: Day 8, 15, 22, 29, 43, 57, 85, 113, 141, 168, 252, 336, 420, 504, 588, 672, 756, 1008, 1092
PK- C Reactive Protein Levels by PK Quartile (AUC0-12)
To define the PK and C Reactive Protein relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
Time frame: 24 weeks
PK- Interleukin 1 Receptor Antagonist Levels by PK Quartile (AUC0-12)
To define the PK and Interleukin 1 Receptor Antagonist relationship relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
Time frame: 24 weeks
PK- Tissue Necrosis Factor Receptor 2 Levels by PK Quartile (AUC0-12)
To define the PK and Tissue Necrosis Factor Receptor 2 relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
Time frame: 24 weeks
AUC 0-Inf
Area Under the Serum Concentration Versus Time Curve,Time 0 to Infinity
Time frame: 0.25 to 0.75, 1 to 3, and 4 to 12 hours postdose on Day 1 and predose, 0.25 to 0.75 hours, and 1 to 3 hours postdose on Day 15, with a random sample on Days 29 and 57
The study was conducted from 03-Mar-2011 to 31-Dec-2019 globally. Participants with MF and baseline PLT of 75 to \< 100 × 109/L are enrolled in Stratum 1;and 50 to \< 75 × 109/L are enrolled in Stratum 2.. The study has a core period (up to week 24) consisting of 2 phases (dose escalation and safety expansion) followed by an extension period (up to 3 years). Participants received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined
| Milestone | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 3 | 20 | 4 | 12 | 3 | 4 | 18 | 0 | 0 |
| Completed | 2 | 1 | 11 | 2 | 3 | 1 | 2 | 3 | 0 | 0 |
| Not completed | 3 | 2 | 9 | 2 | 9 | 2 | 2 | 15 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 4 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 2 | 1 | 5 | 1 | 2 | 5 | 0 | 0 |
DLT was defined as the occurrence of any of the following treatment-related toxicities, occurring through Day 28: Any grade ≥ 2 hemorrhagic event ; Any grade thrombocytopenia requiring PLT transfusion; PLT count \< 25x109/L\*; Grade 4 neutropenia (absolute neutrophil count \< 0.5x109/L)\*; Grade ≥ 3 febrile neutropenia\*; Grade ≥ 2 total serum bilirubin with coincident direct bilirubin ≥ 0.5 mg/dL; Grade 3 non-hematologic toxicity for ≥ 7 consecutive days; Grade 4 non-hematologic toxicity. In the dose escalation stage in the core study period, the starting does in both strata was 5mg bid. Successive cohorts of newly enrolled patients received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined. Initially, only patients with PLT counts 75-99 x10\^9/L (stratum 1) were allowed to be enrolled. Once safety was established in stratum 1 at the first 2 dose cohorts, eligible population was further expanded to patients with PLT counts 50-74 x10\^9/L (stratum 2).
| Participants | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
| Participants | Stratum 1 : Group 1 | Stratum 1 : Group 2 | Stratum 1 : Group 3 | Stratum 2 : Group 1 | Stratum 2 : Group 2 |
|---|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAE's) | 8 | 20 | 16 | 7 | 18 |
Participants achieving ≥ 50% reduction in palpable spleen length relative to study day 1 by treatment and stratum
| Participants | Stratum 1 : Group 1 | Stratum 1 : Group 2 | Stratum 1 : Group 3 | Stratum 2 : Group 1 | Stratum 2 : Group 2 |
|---|---|---|---|---|---|
| Number of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length | 3 | 6 | 4 | 1 | 3 |
Defined as measurement of change in spleen length by palpation from baseline
| cm | Stratum 1 | Stratum 2 |
|---|---|---|
| Day 8 | -2.8 ± 2.73 | -3.7 ± 2.98 |
| Day 15 | -3.3 ± 2.7 | -5.4 ± 4.4 |
| Day 22 | -5.2 ± 2.87 | -5.4 ± 4.81 |
| Day 29 | -4.4 ± 3.14 | -6.0 ± 4.23 |
| Day 43 | -4.6 ± 2.74 | -5.8 ± 4.31 |
| Day 57 | -4.5 ± 2.98 | -5.6 ± 4.52 |
| Day 85 | -4.5 ± 3.53 | -5.2 ± 4.32 |
| Day 113 | -4.7 ± 3.29 | -6.0 ± 4.74 |
| Day 141 | -4.9 ± 3.24 | -6.7 ± 4.43 |
| Day 168 | -5.2 ± 3.73 | -5.0 ± 4.78 |
| Day 252 | -5.5 ± 4.40 | -3.6 ± 6.67 |
| Day 336 | -5.1 ± 4.64 | -5.3 ± 4.86 |
| Day 420 | -6.1 ± 4.80 | -4.9 ± 5.75 |
| Day 504 | -5.7 ± 4.0 | -4.9 ± 4.91 |
| Day 588 | -4.7 ± 5.24 | -5.4 ± 5.61 |
| Day 672 | -5.8 ± 5.33 | -4.4 ± 6.60 |
| Day 756 | -5.7 ± 5.22 | -6.0 ± 6.03 |
| Day 1008 | -7.6 ± 3.93 | -8.0 ± 4.55 |
| Day 1092 | -6.8 ± 1.71 | -4.2 ± 5.81 |
To define the PK and C Reactive Protein relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
| micrograms/mL | Stratum 1 | Stratum 2 |
|---|---|---|
| Quartile 1 Day 1 | 14 ± 5.73 | 12 |
| Quartile 1 Day 29 | 21.2 ± 31.5 | 2.6 ± 2.05 |
| Quartile 1 Day 168 | 7.6 ± 8 | 5.51 ± 4.98 |
| Quartile 2 Day 1 | 9.5 ± 0.707 | 7.7 |
| Quartile 2 Day 29 | 10.2 ± 23.8 | 1.84 ± 173 |
| Quartile 2 Day 168 | 8.37 ± 12.8 | 2.41 ± 1.45 |
| Quartile 3 Day 1 | 6.85 ± 7.28 | 6.5 |
| Quartile 3 Day 29 | 2.76 ± 4.66 | 7.36 ± 9.06 |
| Quartile 3 Day 168 | 7.7 ± 14.9 | 4.98 ± 5.1 |
| Quartile 4 Day 1 | 0.96 ± 1.05 | 5.4 |
| Quartile 4 Day 29 | 1.87 ± 1.43 | 12.4 ± 17.8 |
| Quartile 4 Day 168 | 4.88 ± 9.01 | 4.9 |
To define the PK and Interleukin 1 Receptor Antagonist relationship relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
| picograms/mL | Stratum 1 | Stratum 2 |
|---|---|---|
| Quartile 1 Day 1 | 188 ± 116 | 105 |
| Quartile 1 Day 29 | 267 ± 334 | 588 ± 730 |
| Quartile 1 Day 168 | 592 ± 532 | 379 ± 419 |
| Quartile 2 Day 1 | 179 ± 43.1 | 133 |
| Quartile 2 Day 29 | 524 ± 519 | 600 ± 649 |
| Quartile 2 Day 168 | 557 ± 504 | 334 ± 322 |
| Quartile 3 Day 1 | 319 ± 288 | 191 |
| Quartile 3 Day 29 | 304 ± 327 | 452 ± 529 |
| Quartile 3 Day 168 | 549 ± 531 | 960 ± 792 |
| Quartile 4 Day 1 | 120 ± 40.3 | 148 |
| Quartile 4 Day 29 | 604 ± 647 | 475 ± 464 |
| Quartile 4 Day 168 | 562 ± 758 | 378 |
To define the PK and Tissue Necrosis Factor Receptor 2 relationship using PK Quartiles (AUC 0-12, ng\*h/mL)
| nanograms/mL | Stratum 1 | Stratum 2 |
|---|---|---|
| Quartile 1 Day 1 | 24 ± 19.8 | 6.2 |
| Quartile 1 Day 29 | 20.5 ± 19.7 | 25.7 ± 14.4 |
| Quartile 1 Day 168 | 14 ± 4.24 | 22.6 ± 12.6 |
| Quartile 2 Day 1 | 13.5 ± 0.707 | 8.2 |
| Quartile 2 Day 29 | 14.9 ± 6.62 | 12.3 ± 7.67 |
| Quartile 2 Day 168 | 36.1 ± 22.9 | 18.4 ± 12.6 |
| Quartile 3 Day 1 | 21 ± 9.9 | 47 |
| Quartile 3 Day 29 | 12.9 ± 4.32 | 13.7 ± 11.6 |
| Quartile 3 Day 168 | 13.3 ± 5.8 | 12.4 ± 7.99 |
| Quartile 4 Day 1 | 15 ± 4.24 | 24 |
| Quartile 4 Day 29 | 15.7 ± 9.13 | 24.6 ± 17.4 |
| Quartile 4 Day 168 | 14.3 ± 7.67 | 11 |
Area Under the Serum Concentration Versus Time Curve,Time 0 to Infinity
| nM*hr | 5mg BID | 10mg BID | 15 mg BID |
|---|---|---|---|
| AUC 0-Inf | 1027 ± 357 | 1930 ± 562 | 3756 ± 916 |
Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stratum 1 : Cohort 1 | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Stratum 1 : Cohort 2 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Stratum 1 : Cohort 3 | 3/20 (15%) | 10/20 (50%) | 20/20 (100%) |
| Stratum 1 : Cohort 4 | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Stratum 1 : Cohort 5 | 0/12 (0%) | 5/12 (41.7%) | 12/12 (100%) |
| Stratum 2 : Cohort 1 | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Stratum 2 : Cohort 2 | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Stratum 2 : Cohort 3 | 4/18 (22.2%) | 9/18 (50%) | 18/18 (100%) |
| Stratum 2 : Cohort 4 | — | — | — |
| Stratum 2 : Cohort 5 | — | — | — |
| Event | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/5 | 1/3 | 0/20 | 0/4 | 0/12 | — | — | — | — | — |
| CholelithiasisHepatobiliary disorders | 0/5 | 1/3 | 0/20 | 0/4 | 0/12 | — | — | — | — | — |
| Gallbladder obstructionHepatobiliary disorders | 0/5 | 1/3 | 0/20 | 0/4 | 0/12 | — | — | — | — | — |
| Blood bilirubin increasedInvestigations | 0/5 | 1/3 | 0/20 | 0/4 | 0/12 | — | — | — | — | — |
| Gastric ulcerGastrointestinal disorders | — | — | — | — | — | 1/3 | 0/4 | 0/18 | — | — |
| Multiple organ dysfunction syndromeGeneral disorders | — | — | — | — | — | 1/3 | 0/4 | 1/18 | — | — |
| InfluenzaInfections and infestations | — | — | — | — | — | 1/3 | 0/4 | 1/18 | — | — |
| Splenic ruptureInjury, poisoning and procedural complications | — | — | — | — | — | 1/3 | 0/4 | 0/18 | — | — |
| Sinus node dysfunctionCardiac disorders | 0/5 | 0/3 | 0/20 | 1/4 | 0/12 | — | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/3 | 0/20 | 0/4 | 1/12 | 0/3 | 1/4 | 0/18 | — | — |
| Event | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 |
|---|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 4/5 | 2/3 | 9/20 | 3/4 | 11/12 | 1/3 | 4/4 | 14/18 | — | — |
| AnaemiaBlood and lymphatic system disorders | 3/5 | 2/3 | 11/20 | 2/4 | 6/12 | 1/3 | 3/4 | 8/18 | — | — |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/5 | 0/3 | 1/20 | 0/4 | 3/12 | 0/3 | 3/4 | 3/18 | — | — |
| AstheniaGeneral disorders | 2/5 | 0/3 | 3/20 | 0/4 | 2/12 | 2/3 | 0/4 | 5/18 | — | — |
| PyrexiaGeneral disorders | 1/5 | 0/3 | 6/20 | 0/4 | 2/12 | 2/3 | 1/4 | 4/18 | — | — |
| HyperuricaemiaMetabolism and nutrition disorders | 0/5 | 0/3 | 2/20 | 0/4 | 1/12 | 2/3 | 0/4 | 2/18 | — | — |
| Back painMusculoskeletal and connective tissue disorders | 0/5 | 1/3 | 4/20 | 0/4 | 0/12 | 2/3 | 1/4 | 3/18 | — | — |
| CoughRespiratory, thoracic and mediastinal disorders | 0/5 | 1/3 | 2/20 | 0/4 | 3/12 | 2/3 | 2/4 | 6/18 | — | — |
| EcchymosisSkin and subcutaneous tissue disorders | 0/5 | 2/3 | 6/20 | 0/4 | 0/12 | 1/3 | 1/4 | 2/18 | — | — |
| InsomniaPsychiatric disorders | 3/5 | 0/3 | 0/20 | 0/4 | 1/12 | 1/3 | 1/4 | 1/18 | — | — |
Full Analysis Set
| Age, Continuous(years) | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.00 ± 7.78 | 54.00 ± 4.00 | 63.0 ± 14.71 | 70.4 ± 8.91 | 75.8 ± 3.30 | 67.3 ± 11.06 | 72.5 ± 6.95 | 68.0 ± 11.66 | — | — | 66.4 ± 11.81 |
| Sex: Female, Male(Participants) | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 12 | 2 | 4 | 2 | 3 | 7 | — | — | 36 |
| Male | 1 | 1 | 8 | 2 | 8 | 1 | 1 | 11 | — | — | 33 |
| Race/Ethnicity, Customized(Participants) | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | — | — | 4 |
| Not Hispanic or Latino | 4 | 2 | 15 | 3 | 7 | 2 | 0 | 13 | — | — | 46 |
| Missing | 1 | 1 | 4 | 1 | 5 | 1 | 3 | 3 | — | — | 19 |
| Race/Ethnicity, Customized(Participants) | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White — White | 5 | 2 | 8 | 4 | 11 | 2 | 3 | 16 | — | — | 51 |
| White — Asian | 0 | 1 | 11 | 0 | 0 | 0 | 0 | 0 | — | — | 12 |
| White — Other | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | — | — | 2 |
| White — Missing | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | — | — | 4 |
| ECOG Performance Status(Participants) | Stratum 1 : Cohort 1 | Stratum 1 : Cohort 2 | Stratum 1 : Cohort 3 | Stratum 1 : Cohort 4 | Stratum 1 : Cohort 5 | Stratum 2 : Cohort 1 | Stratum 2 : Cohort 2 | Stratum 2 : Cohort 3 | Stratum 2 : Cohort 4 | Stratum 2 : Cohort 5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 9 | 1 | 6 | 0 | 1 | 4 | — | — | 24 |
| 1 | 3 | 1 | 9 | 1 | 4 | 2 | 2 | 10 | — | — | 32 |
| 2 | 1 | 0 | 2 | 2 | 2 | 1 | 1 | 4 | — | — | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2011 to primary completion in Dec 2019, 105 months.
Results were first posted in Mar 2022, 2 years 2 months after primary completion.
Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 105 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib